Austedo vs Aimovig
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Austedo | US Aimovig | |
|---|---|---|
| Generic name | deutetrabenazine | erenumab |
| Drug class | VMAT2 Inhibitor | CGRP Receptor Antagonist (Biologic) |
| Treats | Tardive dyskinesia, Huntington's chorea | Migraine prevention |
| Category | Neurology | Neurology |
| Manufacturer | Teva | Amgen/Novartis |
| Year approved | 2017 | 2018 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $150M | $100M |
| Common side effects | Depression and suicidal thoughts (Huntington's), Drowsiness, Fatigue, Dry mouth | Constipation, Injection site reactions, Muscle cramps, High blood pressure |
Frequently asked questions
Is Austedo or Aimovig better?
Neither is universally "better." Austedo (deutetrabenazine) and Aimovig (erenumab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Austedo and Aimovig?
Austedo is a VMAT2 Inhibitor made by Teva, while Aimovig is a CGRP Receptor Antagonist (Biologic) made by Amgen/Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Austedo has the larger estimated TV advertising budget of the two.